GF Fund Management
RARE icon

GF Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

GF Fund Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$40.2K Buy
2,677
+632
+31% +$15.2K ﹤0.01% 420
2026
Q2 		$68.3K Sell
2,045
-121
-6% -$3.01K ﹤0.01% 364
2026
Q1 		$45.4K Buy
2,166
+271
+14% +$6.1K ﹤0.01% 412
2025
Q4 		$43.6K Sell
1,895
-178
-9% -$5.85K ﹤0.01% 417
2025
Q3 		$62.4K Sell
2,073
-291
-12% -$8.73K ﹤0.01% 373
2025
Q2 		$86K Hold
2,364
– – ﹤0.01% 379
2025
Q1 		$85.6K Buy
2,364
+425
+22% +$17.7K ﹤0.01% 375
2024
Q4 		$81.6K Buy
+1,939
New +$96.2K ﹤0.01% 347

Other funds holding RARE

GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

GF Fund Management's RARE Position: Q3 2026 in Review

GF Fund Management increased its Ultragenyx Pharmaceutical (RARE) stake by 31% in Q3 2026, buying an estimated $15.2K and bringing the position to 2,677 shares worth $40.2K. The position accounts for ﹤0.01% of the portfolio, ranked #420.

GF Fund Management first reported a position in RARE in Q4 2024 and has held it in 8 quarters since. The position peaked at $86K in Q2 2025. 113 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • GF Fund Management held 2,677 shares of Ultragenyx Pharmaceutical worth $40.2K as of Q3 2026.
  • GF Fund Management bought 632 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $15.2K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #420 holding.
  • GF Fund Management first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 8 quarters since.
  • GF Fund Management's Ultragenyx Pharmaceutical position peaked at $86K in Q2 2025.
  • 113 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.